novo obesity - Search News

Novo Nordisk Shares Fall

Data on new Novo Nordisk obesity drug disappoints in trial, shares drop

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.

The Wall Street Journal on MSN · 2d

Novo Nordisk Shares Fall After Latest CagriSema Obesity Drug Trial Results

New trial data showed the drug helped obese or overweight type 2 diabetics lose an average 15.7% of their weight, when an earlier study recorded 22.7%.

Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial

Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.

Novo Nordisk Skeptic Finally Upgrades Stock

Seeking Alpha on MSN · 9h

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read more here.

Markets Insider · 7h

Why This Long-Time Skeptic Finally Upgraded Novo Nordisk (NVO) to Buy

Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after

Bloomberg L.P. · 10h

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting coverage of the stock.

Roche, Zealand Pharma and obesity

Pharmalittle: We’re reading about a Roche deal for an obesity drug, a Gilead HIV drug and more

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital increase.

The Wall Street Journal on MSN · 1d

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.

Reuters on MSN · 1d

Roche secures Zealand obesity drug candidate for up to $5.3 billion

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.

4h

AbbVie Is Preparing To Challenge Eli Lilly And Novo Nordisk

AbbVie Inc. enters the obesity market with GUBamy, a promising amylin analog. Click here to find out why ABBV stock is a Buy.

Verywell Health on MSN2d

Novo Nordisk Offers Wegovy for $499 a Month in Direct-to-Consumer Program

Novo Nordisk announced a direct-to-consumer program that allows patients to buy Wegovy out of pocket at a lower cost.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results